The race for a coronavirus vaccine heats up
Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
Shares in AstraZeneca bounced this week after the US government signalled that it is considering fast-track approval for the group’s Covid-19 vaccine. In April AstraZeneca agreed a deal with Oxford University, which originally discovered the vaccine, to develop and distribute it.
The government could ask the US Food and Drug Administration (FDA) to grant an “emergency use authorisation” (EUA) based on data from the final-stage UK trial, rather than wait for the more extended study normally required by US regulators. Such a move, possible as early as September, would allow President Donald Trump to claim he has “turned the tide” on the virus. Not so fast, say Rhys Blakely and Henry Zeffman in The Times. AstraZeneca says it is “too early” to begin talks with US regulators about an EUA. Nonetheless, 17,000 people have been enrolled in trials in Britain, South Africa and Brazil. So if enough data emerged to convince AstraZeneca to apply for an EUA, the FDA would be under pressure to grant it quickly. It has already approved 21 Covid-19 drugs, including an antibody treatment, on an emergency basis.
Meanwhile, says Bloomberg, Pfizer and BioNTech claim that their joint Covid-19 vaccine is “on track” to be submitted for regulatory review “as early as October”. The companies, which recently clinched a $2bn deal to supply 100 million doses to the US government, released more detailed data from early-stage trials suggesting that the drug was “well tolerated” with “mild to moderate fever in fewer than 20% of participants”.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
8 of the best properties for sale with minstrels’ galleriesThe best properties for sale with minstrels’ galleries – from a 15th-century house in Kent, to a four-storey house in Hampstead, comprising part of a converted, Grade II-listed former library
-
The rare books which are selling for thousandsRare books have been given a boost by the film Wuthering Heights. So how much are they really selling for?
-
8 of the best properties for sale with minstrels’ galleries
The best properties for sale with minstrels’ galleries – from a 15th-century house in Kent, to a four-storey house in Hampstead, comprising part of a converted, Grade II-listed former library
-
The rare books which are selling for thousands
Rare books have been given a boost by the film Wuthering Heights. So how much are they really selling for?
-
How to invest as the shine wears off consumer brandsConsumer brands no longer impress with their labels. Customers just want what works at a bargain price. That’s a problem for the industry giants, says Jamie Ward
-
A niche way to diversify your exposure to the AI boomThe AI boom is still dominating markets, but specialist strategies can help diversify your risks
-
New PM Sanae Takaichi has a mandate and a plan to boost Japan's economyOpinion Markets applauded new prime minister Sanae Takaichi’s victory – and Japan's economy and stockmarket have further to climb, says Merryn Somerset Webb
-
Early signs of the AI apocalypse?Uncertainty is rife as investors question what the impact of AI will be.
-
8 of the best properties for sale with beautiful kitchensThe best properties for sale with beautiful kitchens – from a Modernist house moments from the River Thames in Chiswick, to a 19th-century Italian house in Florence
-
Three key winners from the AI boom and beyondJames Harries of the Trojan Global Income Fund picks three promising stocks that transcend the hype of the AI boom
